レッドバイオテクノロジーの世界市場：市場規模・シェア分析 (用途別・製品別・エンドユーザー別)、産業需要の予測 (～2030年)

主なハイライト

世界のレッドバイオテクノロジー市場は、2023年に5,767億米ドル、2030年には1兆1,723億米ドルの規模に達し、10.5%以上のCAGRで成長する見通しです。

臨床試験・創薬・保因者スクリーニング・診断におけるニーズの高まりと、遺伝性疾患の罹患率の上昇が、業界の拡大を後押ししています。

主要な洞察

バイオ医薬品生産は2023年に25.0%のシェアで業界をリードし、この10年間はさらにリードし続ける見通しです。

2023年にはヒトワクチンが30.0%のシェアで業界をリードし、この10年間はこの傾向が続く見通しです。

2023年には北米が約55%のシェアで業界をリードしており、今後数年間はさらに堅調な伸びを示す見通しです。

アジア太平洋は最も速いペースで進歩しています。これは、この地域の海外および国内のバイオテクノロジー企業からの資金調達が増加していること、感染症や慢性疾患の患者が膨大に存在することに拠ります。

当レポートでは、世界のレッドバイオテクノロジーの市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、用途別・製品別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：用途別 (2017～2030年)
• 市場収益：製品別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：用途別 (2017～2030年)
• 市場収益：製品別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：用途別 (2017～2030年)
• 市場収益：製品別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Gilead Sciences Inc.
• Novartis AG

第31章 付録

Key Highlights

The red biotechnology market generated a value of USD 576.7 billion in 2023, and it will increase to USD 1,172.3 billion, advancing at more than 10.5% compound annual growth rate, by 2030.

The increasing need for it in clinical trials, drug discovery, carrier screening, and diagnostics, along with the rising incidence of genetic disorders aid the industry expansion.

Effective product development as well as genetic engineering relating to new drugs for treating life-threatening ailments are the key benefits of red biotechnology.

The increasing technological advancement rate in gene sequencing platforms, rising investment from private bodies and government for large-scale biotechnology plans, and substantial acceptance of red biotechnology across different applications like veterinary sciences, tissue engineering, and poultry farming, resulted in the industry expansion.

The increasing incidence of cancer and the surging use of this technology in cancer research & diagnostics are major drivers for this industry.

These technologies are employed for producing combination vaccines, including those that target Hepatitis A, Hepatitis B, polio, and diphtheria at once.

The rising count of R&D initiatives by major players, particularly in the area of stem cells, is a major trend in this industry.

Likewise, the pandemic of COVID-19 and a rising count of research studies discovering the use of this method for developing medicines, vaccines, and diagnostic tools assist industry expansion.

Key Insights

Biopharmaceutical production led the industry in 2023, with a 25.0% share, and it will further remain leading throughout this decade.

The increasing need for proteins, antibodies, antisense oligonucleotides, RNA, and DNA for diagnostic and therapeutic purposes is boosting the biopharmaceutical production category growth.

Gene therapy is likely to propel at the fastest compound annual growth rate in the years to come. The increasing incidence of genetic disorders as well as cancers is driving this category.

The human vaccines category led the industry in 2023, with a share of 30.0%, and it will continue this trend throughout this decade.

The human vaccines category growth is because of the increasing occurrence of infectious disease outbreaks and the rising prevalence of chronic ailments.

The biopharmaceutical industry was the largest contributor to the industry in 2023, with a 40.0% share, and it is likely to remain the largest during this decade.

The enhancing biopharmaceutical production infrastructure and R&D globally, to discover new molecule entities & vaccines against infectious ailments is driving the human vaccines category growth.

North America led the industry in 2023, with approximately 55% share, and it will further advance at a robust rate in the years to come.

The dominance of North America is because of the increasing incidence of rare, genetic, and chronic illnesses; the high technological improvement rate in the healthcare sector, and the rising number of R&D initiatives.

APAC is advancing at the fastest rate. This is because of the rising funding from both overseas and domestic biotech firms in this region and an enormous pool of patients with infectious and chronic ailments.

The red biotechnology industry is fragmented in nature, with the significant existence of large-scale companies.

These companies are involved in product launches, new product development, agreements, mergers, partnerships, and product approval to enhance their market presence.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by application
  • 1.4.2. Market size breakdown, by product
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Application (2017-2030)
• 6.3. Market Revenue, by Product (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Application (2017-2030)
• 7.3. Market Revenue, by Product (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Application (2017-2030)
• 8.3. Market Revenue, by Product (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Application (2017-2030)
• 9.3. Market Revenue, by Product (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Application (2017-2030)
• 10.3. Market Revenue, by Product (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Application (2017-2030)
• 11.3. Market Revenue, by Product (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Application (2017-2030)
• 12.3. Market Revenue, by Product (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Application (2017-2030)
• 13.3. Market Revenue, by Product (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Application (2017-2030)
• 14.3. Market Revenue, by Product (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Application (2017-2030)
• 15.3. Market Revenue, by Product (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Application (2017-2030)
• 16.3. Market Revenue, by Product (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Application (2017-2030)
• 17.3. Market Revenue, by Product (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Application (2017-2030)
• 18.3. Market Revenue, by Product (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Application (2017-2030)
• 19.3. Market Revenue, by Product (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Application (2017-2030)
• 20.3. Market Revenue, by Product (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Application (2017-2030)
• 21.3. Market Revenue, by Product (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Application (2017-2030)
• 22.3. Market Revenue, by Product (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Application (2017-2030)
• 23.3. Market Revenue, by Product (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Application (2017-2030)
• 24.3. Market Revenue, by Product (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Application (2017-2030)
• 25.3. Market Revenue, by Product (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Application (2017-2030)
• 26.3. Market Revenue, by Product (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Application (2017-2030)
• 27.3. Market Revenue, by Product (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Application (2017-2030)
• 28.3. Market Revenue, by Product (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Pfizer Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. F. Hoffmann-La Roche Ltd.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Merck KGaA
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. AstraZeneca PLC
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Takeda Pharmaceutical Company Limited
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Amgen Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Regeneron Pharmaceuticals Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Gilead Sciences Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Novartis AG
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports